Abstract
The classical attitude of Nuclear Medicine practitioners on matters of peptide-receptor interactions has maintained an intrinsic monogamic character since many years. New advances in the field of biochemistry and even in clinical Nuclear Medicine have challenged this type of thinking, which prompted me to work on this review. The central issue of this paper will be the use of somatostatin analogs, i.e., octreotide, in clinical imaging procedures as well as in relation to neuroendocirne tumors. Newly described characteristics of G-protein coupled receptors such as the formation of receptor mosaics will be discussed. A small section will enumerate the regulatory processes found in the cell membrane. Possible new interpretations, other than tumor detection, based on imaging procedures with somatostatin analogs will be presented. The readers will be taken to situations such as inflammation, nociception, mechanosensing, chemosensing, fibrosis, taste, and vascularity where somatostatin is involved. Thyroid-associated orbitopathy will be used as a model for the development of multi-agent therapeutics. The final graphical summary depicts the multifactorial properties of ligand binding.
Highlights
The classical attitude of Nuclear Medicine practitioners on matters of peptide-receptor interactions has maintained an intrinsic monogamic character since many years
These data seem to contradict some views of ligand-receptor interactions which constitute the basis of the biochemical and Correspondence: Roy.Moncayo@i-med.ac.at 1Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria Full list of author information is available at the end of the article pharmaceutical work that is daily applied in Nuclear Medicine imaging
Introduction: the basics of receptor binding and the use of octreotide The concepts regarding receptor function have been accommodated over time to a reductionist model that ideally considers one ligand and one receptor
Summary
Melis M, Forrer F, Capello A, Bijster M, Bernard BF, Reubi JC, et al: Upregulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al: 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. Pan Q, Li DG, Lu HM, Lu LY, You HN, Xu QF: Relationship between somatostatin receptors and activation of hepatic stellate cells. Van Op dB, van Nassauw L, Lantermann K, van Marck E, Timmermans JP: Effect of intestinal inflammation on the cell-specific expression of somatostatin receptor subtypes in the murine ileum.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have